Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases

Naseema Gangat,Paola Guglielmelli,Natasha Szuber,Kebede H. Begna,Mrinal M. Patnaik,Mark R. Litzow,Aref Al‐Kali,James M. Foran,Jeanne M. Palmer,Hassan Alkhateeb,Michelle A. Elliott,Curtis A. Hanson,Animesh Pardanani,Francesco Mannelli,Alessandro M. Vannucchi,Ayalew Tefferi
DOI: https://doi.org/10.1002/ajh.26186
IF: 13.265
2021-05-06
American Journal of Hematology
Abstract:<p>Venetoclax (Ven) combined with a hypomethylating agent (HMA) has now emerged as an effective treatment regimen for acute myeloid leukemia, in both <i>de novo</i> and relapsed/refractory setting. The current multicenter study retrospectively examined Ven+HMA treatment outcome among 32 patients (median age 69 years; 59% males) with blast‐phase myeloproliferative neoplasm (MPN‐BP). Pre‐leukemic phenotype included essential thrombocythemia (ET)/post‐ET myelofibrosis (34%), polycythemia vera (PV)/post‐PV myelofibrosis (38%) and primary myelofibrosis (28%). Twenty‐nine study patients were fully annotated cytogenetically and molecularly (NGS): 69% harbored complex karyotype and/or mutations, including <i>TP53</i> (41%), <i>IDH1/2</i> (21%), <i>ASXL1</i> (21%), <i>N/KRAS</i> (14%), <i>SRSF2</i> (10%), <i>EZH2</i> (10%) and <i>U2AF1</i> (7%). All patients received Ven combined with either azacitidine (<i>n</i>=12) or decitabine (<i>n</i>=20); either upfront (<i>n</i>=23) or after failing another induction therapy (<i>n</i>=9). Complete remission with (CR) or without (CRi) count recovery was achieved in 14 (44%) patients and was more likely to occur in the absence of pre‐leukemic PV/post‐PV myelofibrosis phenotype (p&lt;0.01), complex karyotype (p&lt;0.01) or <i>K/NRAS</i> (p=0.03) mutations; 7 of 8 patients (88%) without vs 4 of 21 (19%) with complex karyotype or <i>K/NRAS</i> mutation achieved CR/CRi (p&lt;0.01); all 11 informative patients with pre‐leukemic PV/post‐PV myelofibrosis phenotype displayed complex karyotype (p&lt;0.01). In contrast, neither <i>TP53</i> (p=0.45) nor <i>IDH1/2</i> (p=0.63) mutations affected response. Compared to historical controls treated with HMA alone (<i>n</i>=26), the CR/CRi rate (44% vs 4%) and median survival (8 vs 5.5 months) were more favorable with Ven+HMA, but without significant difference in overall survival. Importantly, 6 patients with CR/CRi subsequently received allogeneic hematopoietic stem cell transplant (AHSCT). Ven+HMA produces robust CR/CRi rates in MPN‐BP, especially in the absence of <i>RAS</i> mutations and complex karyotype, thus enabling AHSCT, in some patients.</p><p>This article is protected by copyright. All rights reserved.</p>
What problem does this paper attempt to address?